• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    2/14/23 4:21:25 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $SEER alert in real time by email
    SC 13G/A 1 tm236774d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No. 2)*

     

     

     

    SEER, INC.

    (Name of Issuer)

     

     

     

    Class A Common Stock, $0.00001 par value per share

    (Title of Class of Securities)

     

    81578P 106

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    ¨Rule 13d-1(c)
    xRule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 81578P 106 Page 2

     

                 
    1   

    NAME OF REPORTING PERSON:

     

    Omid Farokhzad

       

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

     

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a)   ¨        

    (b)   ¨

    3  

    SEC USE ONLY:

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    United States 

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        5   

    SOLE VOTING POWER

     

    2,634,224 (1)(2)

        6  

    SHARED VOTING POWER

     

    3,420,616 (2)(3)

        7  

    SOLE DISPOSITIVE POWER

     

    2,634,224 (1)(2)

        8  

    SHARED DISPOSITIVE POWER

     

    3,420,616 (2)(3)

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    6,054,840 (1)(2)(3)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):     ¨   

     

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    9.4 (2)(4)(5)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    IN

    (1) Consists of (i) 392,763 shares of Class A common stock and 134,579 shares of Class B common stock held of record by Omid Farokhzad (the “Reporting Person”); (ii) 2,035,222 shares of Class A common stock subject to options exercisable within 60 days of December 31, 2022 and (iii) 71,660 shares of Class A common stock issuable upon vesting of RSUs within 60 days of December 31, 2022.
    (2) Each share of Class B common stock is convertible at any time into one share of Class A common stock.
    (3) Consists of (i) 1,303,478 shares of Class B common stock held of record by Dynamics Group LLC for which the Reporting Person serves as the sole member and (ii) 2,117,138 shares of Class B common stock held of record by SAF-BND Trust for which the Reporting Person’s spouse serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the SAF-BND Trust.
    (4) Based on the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Person as set forth in Row 9 by (b) the sum of (i) 58,596,598 shares of Class A common stock outstanding as of November 4, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, filed with the Securities and Exchange Commission on November 8, 2022 (the “Form 10-Q”); (ii) 3,555,195 shares of Class B common stock beneficially owned by the Reporting Person; (iii) 2,035,222 shares of Class A common stock subject to options exercisable within 60 days of December 31, 2022 and (iv) 71,660 shares of Class A common stock issuable upon vesting of RSUs within 60 days of December 31, 2022. The aggregate number of shares of Class B common stock beneficially owned by the Reporting Person as set forth in clause “(a)” of this footnote are treated as converted into Class A common stock only for the purpose of computing the percentage ownership of the Reporting Person.
    (5) Each share of Class A common stock is entitled to one vote and each share of Class B common stock is entitled to ten votes. The percentage reported does not reflect the ten for one voting power of the Class B common stock because these shares are treated as converted into Class A common stock for the purpose of this report.

     

     

     

     

    Item 1

     

    (a)Name of Issuer:

     

    Seer, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    3800 Bridge Parkway, Suite 102

    Redwood City, California 94065

     

    Item 2

     

    (a)Name of Person Filing:

     

    Omid Farokhzad

     

    (b)Address or principal business office or, if none, residence:

     

    The address for the principal business office of Dr. Farokhzad is:

     

    c/o Seer, Inc.

    3800 Bridge Parkway, Suite 102

    Redwood City, California 94065

     

    (c)Citizenship:

     

    United States

     

    (d)Title and Class of Securities:

     

    Class A common stock, par value, $0.00001 per share.

     

    (e)CUSIP No.:

     

    81578P 106

     

    Item 3.If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership

     

    (a)Amount beneficially owned: 6,054,840

     

    (b)Percent of class: 9.4

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to direct the vote: 2,634,224 (1)(2)

     

    (ii)Shared power to direct the vote: 3,420,616 (2)(3)

     

    (iii)Sole power to dispose or to direct the disposition of: 2,634,224 (1)(2)

     

    (iv)Shared power to dispose or to direct the disposition of: 3,420,616 (2)(3)

     

    (1) Consists of (i) 392,763 shares of Class A common stock and 134,579 shares of Class B common stock held of record by Omid Farokhzad (the “Reporting Person”); (ii) 2,035,222 shares of Class A common stock subject to options exercisable within 60 days of December 31, 2022 and (iii) 71,660 shares of Class A common stock issuable upon vesting of RSUs within 60 days of December 31, 2022.

     

    (2) Each share of Class B common stock is convertible at any time into one share of Class A common stock.

     

    (3) Consists of (i) 1,303,478 shares of Class B common stock held of record by Dynamics Group LLC for which the Reporting Person serves as the sole member and (ii) 2,117,138 shares of Class B common stock held of record by SAF-BND Trust for which the Reporting Person’s spouse serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the SAF-BND Trust.

     

     

     

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6.Ownership of More than 5 Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.          Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certifications

     

    Not applicable.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2023  
       
      /s/ Omid Farokhzad
      Omid Farokhzad

     

     

     

    Get the next $SEER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEER

    DatePrice TargetRatingAnalyst
    5/4/2026$4.00Buy
    Canaccord Genuity
    7/5/2023$10.00Neutral
    JP Morgan
    1/4/2023$9.00 → $6.50Neutral → Underperform
    BofA Securities
    8/11/2022$20.00 → $12.00Overweight → Neutral
    JP Morgan
    3/1/2022$23.00 → $21.00Equal-Weight
    Morgan Stanley
    2/15/2022$46.00 → $23.00Equal-Weight
    Morgan Stanley
    10/15/2021Outperform
    Cowen
    8/13/2021$55.00 → $50.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SEER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CFO Horn David R. sold $12,352 worth of shares (7,303 units at $1.69), decreasing direct ownership by 1% to 493,959 units (SEC Form 4) (tax liability)

    4 - Seer, Inc. (0001726445) (Issuer)

    5/21/26 5:12:54 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Commercial Officer Bazarko Anthony R. was granted 75,000 shares (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    5/11/26 6:20:12 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Bazarko Anthony R.

    3 - Seer, Inc. (0001726445) (Issuer)

    5/11/26 6:19:02 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

    Reinforces Seer's Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity Illustrates Why Radoff and Torok's Short-Term Campaign Risks Disrupting Seer's Momentum and Undermines Stockholder Value Urges Stockholders to Vote "FOR" ONLY Seer's Director Nominees on the BLUE Proxy Card REDWOOD CITY, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on July 28, 2026. Stockholders of record as of

    6/3/26 6:00:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Files ITC Complaint Against Nanomics

    REDWOOD CITY, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has filed a complaint at the United States International Trade Commission (ITC) against Nanomics Biotechnology Co., Ltd. The Brigham and Women's Hospital has joined the ITC complaint as well. The ITC complaint builds on the patent infringement suit filed in federal district court on May 12, 2026, and is based on Nanomics' infringement of U.S. Patent Nos. 11,435,360, 11,630,112, 12,050,222, 12,228,566, and 12,590,948, which protect Seer's intellectual property in the field of nanoparticle protein enrichment. Seer's ITC

    5/29/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    The Radoff-JEC Group Calls on Seer Inc. and Its Advisors to Reevaluate Its Premium Acquisition Proposal in the Best Interests of All Stockholders

    Corrects the Board's Flawed Reasons for Rejecting its Credible, Premium Acquisition Offer in Apparent Breach of its Fiduciary Duty Reaffirms its Fully Financed Proposal to Acquire Seer for $2.40 per Share in Cash – a 42% Premium to the Unaffected Share Price – and a CVR for Stockholders to Receive 80% of the Net Proceeds from the Company's Assets Files Preliminary Proxy Statement to Give Stockholders the Opportunity to Elect Three New Qualified, Independent Directors Who Intend to Advocate for a Strategic Review Process Aimed at Maximizing Value for All Seer Stockholders Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group" or "we"), wh

    5/27/26 4:30:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    SEC Filings

    View All

    SEC Form DFRN14A filed by Seer Inc.

    DFRN14A - Seer, Inc. (0001726445) (Subject)

    6/4/26 5:02:22 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEFA14A filed by Seer Inc.

    DEFA14A - Seer, Inc. (0001726445) (Filer)

    6/3/26 5:24:15 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEFA14A filed by Seer Inc.

    DEFA14A - Seer, Inc. (0001726445) (Filer)

    6/3/26 5:22:33 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Seer with a new price target

    Canaccord Genuity initiated coverage of Seer with a rating of Buy and set a new price target of $4.00

    5/4/26 8:35:45 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    JP Morgan resumed coverage on Seer with a new price target

    JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00

    7/5/23 7:25:16 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by BofA Securities with a new price target

    BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously

    1/4/23 9:03:59 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Leadership Updates

    Live Leadership Updates

    View All

    Seer Announces Appointment of Anthony Bazarko as Chief Commercial Officer

    Seasoned life sciences executive brings extensive global commercial leadership to accelerate growth and expand adoption of Seer's Proteograph® Product Suite REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced the appointment of Anthony Bazarko as Chief Commercial Officer. Mr. Bazarko brings more than two decades of commercial leadership experience across the life sciences, diagnostics, and biotechnology industries, with a demonstrated track record of driving revenue growth, building high-performing teams, and leading global go-to-market strategies. Mr. Bazarko joins Seer from

    5/4/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Appoints Isaac Ro to its Board of Directors

    REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. "We are excited to welcome Isaac to our board," said Omid Farokhzad, Chair and CEO of Seer. "Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform." "I'm looking forward to work

    9/2/25 7:00:00 AM ET
    $SEER
    $WGS
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Retail: Computer Software & Peripheral Equipment
    Technology

    Seer Appoints Nicolas Roelofs to its Board of Directors

    REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life

    8/14/24 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Financials

    Live finance-specific insights

    View All

    Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

    Reinforces Seer's Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity Illustrates Why Radoff and Torok's Short-Term Campaign Risks Disrupting Seer's Momentum and Undermines Stockholder Value Urges Stockholders to Vote "FOR" ONLY Seer's Director Nominees on the BLUE Proxy Card REDWOOD CITY, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on July 28, 2026. Stockholders of record as of

    6/3/26 6:00:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

    REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended March 31, 2026. Recent Highlights Achieved revenue of $2.8 million in the first quarter of 2026Achieved a doubling of independent publications year-over-year to 84 total, accelerating third-party validation of Seer's platformSecured a collaboration with Precision Health Research, Singapore to provide deep, unbiased proteomics on 10,000 samples for their PRECISE-SG100K study, a landmark multi-ancestry, population-scale cohort of approximately 100,000 Singapo

    5/13/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer to Report First Quarter 2026 Financial Results on May 13, 2026

    REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the first quarter 2026 on Wednesday, May 13, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer, Inc. (NASDAQ:SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, pr

    4/29/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    8/2/24 6:33:25 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    7/8/24 4:32:39 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    4/10/24 10:06:09 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials